- /
- Supported exchanges
- / CO
- / BAVA.CO
Bavarian Nordic (BAVA CO) stock market data APIs
Bavarian Nordic Financial Data Overview
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Bavarian Nordic (top by weight)
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Bavarian Nordic data using free add-ons & libraries
Get Bavarian Nordic Fundamental Data
Bavarian Nordic Fundamental data includes:
- Net Revenue: 6 338 M
- EBITDA: 1 782 M
- Earnings Per Share: 19
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-20
- EPS/Forecast: 4.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bavarian Nordic News
New
Bavarian Nordic (CPSE:BAVA) Stock Could Be Undervalued Despite Its 64% Run
Bavarian Nordic has put in a strong three year share price run, while fresh optimism around its vaccines business has sharpened the focus on what the current valuation implies about the cash the compa...
Bavarian Nordic (CPSE:BAVA) Could Be 16% Below Fair Value As 2026 Guidance Rises
Bavarian Nordic (CPSE:BAVA) raised its full-year 2026 guidance following stronger Travel Health activity, with increased rabies vaccine demand in the US supporting both a higher revenue outlook and a ...
Bavarian Nordic rises after guidance upgrade on U.S. rabies vaccine demand
Investing.com -- Bavarian Nordic shares rose around 4% Thursday after the company raised its full-year 2026 guidance again, lifting its revenue and profitability outlook on stronger-than-expected sale...
Bavarian Nordic Upgrades Full-Year 2026 Financial Guidance After Strong Travel Health Performance
Bavarian Nordic A/S Revenue and EBITDA margin expectations increased, driven by stronger-than-expected Travel Health sales COPENHAGEN, Denmark, October 8, 2026 – Bavarian Nordic A/S (OMX: BAVA) to...
Corporate Events Calendar & News package for
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.